SOURCE: Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc.

June 18, 2013 09:00 ET

Therapeutic Solutions International, Inc. Announces Definitive Agreement With S4S (UK) Limited

TSI Obtains Exclusive Distribution Rights to FDA Cleared and Patented Sleep Appliance Hardware

OCEANSIDE, CA--(Marketwired - Jun 18, 2013) - Therapeutic Solutions International, Inc. (OTCQB: TSOI) announced today the signing of a Distribution Agreement with S4S (UK) Limited for exclusive distribution rights in the United States to market the U.S. patented and FDA cleared titratable sleep appliance hardware sold under the trademark "Sleepwell™".

"Today was a major achievement and milestone for S4S and our ever popular Sleepwell™ appliance, which has been so successful in Europe," stated Matt Everatt, Technical Director of S4S (UK) Limited. "Our signing of this agreement with TSI to exclusively distribute the Sleepwell appliance hardware will give US dentists a new product that can help individuals suffering from snoring and sleep apnea."

Dr. Barry Glassman, VP of Education and Training of Therapeutic Solutions International, stated, "This proven technology is a very attractive choice for both the dentist providing oral appliance therapy, and for the patient seeking an alternative treatment for sleep disturbed breathing, compared to the traditional therapies including surgery and CPAP."

"We at TSI are excited about bringing this quality yet cost effective appliance choice to the United States," said CEO Tim Dixon of Therapeutic Solutions International, who added, "According to the US Department of Health and Human Services the prevalence of sleep apnea in the US population is similar to asthma (20 million patients) and diabetes (23.6 million patients). We look forward to working with dentists and dental laboratories in bringing this product to the patient."

Sleepwell™ components are used to manufacture the appliance in a dental laboratory using a bilaminate material customized to the patient's teeth with a special soft inner lining for maximum comfort and retention. The appliance also incorporates a specially designed component made from medical grade 316 Stainless Steel, which ensures that the lower jaw is held in a forward position while permitting the wearer side-to-side movement during sleep. 

Therapeutic Solutions International is also a global manufacturer of the chairside anterior midpoint stop appliance (AMPSA) devices marketed internationally under the trade names Migran-X® and AMPSA CS®, which have helped countless patients prevent debilitating migraine and tension headache pain, bruxism, clenching, grinding, and TMJ disorders. The Migran-X® and AMPSA CS® devices are the most effective non-drug US FDA cleared dental method of migraine prevention on the market today.

About Therapeutic Solutions International, Inc.

The Company's corporate website is Non-US dentists and physicians can order our AMPSA products at For the Sleepwell™ product, clinical data can be viewed at

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at

Contact Information

  • For more information please contact:
    Therapeutic Solutions International, Inc.